CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I

CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I

The CD20 mAbs, rituximab (RTX) and ofatumumab (OFA), have been used with success in the clinic in the treatment of B cell malignancies. These mAbs can eliminate B cells only by utilizing the body’s immune effector mechanisms, and there is considerable evidence that OFA is particularly effective at e...

Full description

Bibliographic Details
Main Authors: Margaret A. Lindorfer, Paul V. Beum, Ronald P. Taylor
Format: Article
Language:English
Published: MDPI AG 2013-11-01
Series:Antibodies
Subjects:
monoclonal antibody
complement
Factor I
rituximab
ofatumumab
Online Access:http://www.mdpi.com/2073-4468/2/4/598

Similar Items

Similar Items